Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Ensuring equity in the era of HLA-restricted cancer therapeutics

1 Nov 2022

Abstract excerpt

In January 2022, the US Food and Drug Administration granted regulatory approval to tebentafusp, a bispecific T cell receptor protein that targets melanoma antigen gp100 in the context of the human leucocyte antigen (HLA) A*0201 allele. This approval generated significant excitement, given the relative paucity of effective systemic therapies for advanced uveal melanoma. More broadly, tebentafusp represents the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research
Share to Immunotherapy and Immune Responses
Share to Ocular Oncology and Treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 36442912
DOI: 10.1136/jitc-2022-005600

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Ensuring equity in the era of HLA-restricted cancer therapeuticsPMID 36442912Read ↗

Advancing human leukocyte antigen-based cancer immunotherapy: from personalized to broad-spectrum strategies for genetically heterogeneous populations.Semantic proximity Read ↗

Tebentafusp elicits on-target cutaneous immune responses driven by cytotoxic T cells in uveal melanoma patientsSemantic proximity Read ↗

Eligibility for Human Leukocyte Antigen-Based Therapeutics by Race and Ethnicity.Semantic proximity Read ↗

Uzatresgene autoleucel autologous T-cell monotherapy for advanced solid tumors: SURPASS, a phase 1, open-label trialSemantic proximity Read ↗

Analysis of Human Leukocyte Antigen DR Alleles, Immune-Related Adverse Events, and Survival Associated With Immune Checkpoint Inhibitor Use Among Patients With Advanced Malignant Melanoma.Semantic proximity Read ↗

Retrospective analysis of cutaneous immune-related adverse events following checkpoint inhibitor therapy in melanoma patients reveals increased risk associated with the HLA-B*51:01 allele.Semantic proximity Read ↗

Pan-cancer HLA Gene-mediated Tumor Immunogenicity and Immune EvasionSemantic proximity Read ↗

Characteristics and Developmental Trajectory of Clinical Trials Focused on Tumor-Infiltrating Lymphocytes for Cancer TreatmentSemantic proximity Read ↗

HLA Genotype is Associated With Clinical Outcomes to anti-PD1 Therapy in Advanced MelanomaSemantic proximity Read ↗

Engineered CD4 TCR T cells with conserved high-affinity TCRs targeting NY-ESO-1 for advanced cellular therapies in cancerSemantic proximity Read ↗

Enhancing HLA-DR in Cytotoxic T Lymphocytes is crucial for the development of efficient adoptive T cell Therapies for Breast CancerSemantic proximity Read ↗

Reassessing human MHC-I genetic diversity in T cell studies.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.